(Open access funding provided by Semmelweis University)
Szakterületek:
Farmakológia és gyógyszerészet
Most of the people who suffered from COVID-19 fully recovered, but approximately 10-20%
of them developed a wide variety of symptoms after they recover from their initial
illness. Long COVID can develop at any patient; however, several studies suggest that
the development of Long Covid syndrome may be linked to severity of acute illness.
Some of the risk factors are hospitalization (with mechanical ventilation), Intensive
Care Unit admission, age (over 50 years), gender (female) and comorbidities. Since
the precise mechanism of Long COVID has not been clarified, neither the management
of Long COVID-19 syndrome has been solved yet. Promising results have been published
with vaccines as they effectively reduced the risk of Long COVID; however, other data
suggest that vaccination results only partial protection in the post-acute phase of
the disease. Recently, the orally effective antiviral agents (Paxlovid, molnupiravir)
are preferred for outpatient management, and they highly reduce the progression of
mild-to-moderate COVID-19 to severe one, and consequently, might reduce the development
of Long COVID. Finally, recently, several clinical trials are in progress with either
dietary supplements or drugs with different mechanisms of action. Additional information
on the precise mechanisms, risk factors of Long COVID may result in successful preventive
and therapeutic management of Long Covid 19 syndrome.
